Dapiprazole



Cat. No.:	HY-A0142
CAS No.:	72822-12-9
Molecular Formula:	$C_{19}H_{27}N_5$
Molecular Weight:	325.45
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Dapiprazole is a potent, selective and orally active alpha-1 adrenoceptor antagonist. Dapiprazole suppresses the opioid withdrawal symptoms. Dapiprazole is also used as eye drops for reversing mydriasis[1][2][3].
IC_{50} & Target	α1-adrenergic receptor
In Vivo	Dapiprazole hydrochloride (0-10 mg/kg or 0-3 mg/mice; i.p. or i.c.v.; once) reduces the overall severity of the opiate withdrawal symptoms in mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss Albino male CD-1 mice weighing 20 -25 g, acute dependence model[1]
Dosage:	5, 7.5 and 10 mg/kg (i.p.) or 0.5, 1 and 3 mg/mice (i.c.v.), once
Administration:	Intraperitoneal injection or intracerebroventricular administration, once
Result:	Decreased jumping behavior, head shakes and paw shakes when administered just before naloxone.

REFERENCES

[1]. Valeri P, et al. Effects of dapiprazole, clonidine and yohimbine on the development of dependence and withdrawal behaviour in mice. Drug Alcohol Depend. 1989 Jan;23(1):73-7.

[2]. Allinson RW, et al. Reversal of mydriasis by dapiprazole. Ann Ophthalmol. 1990 Apr;22(4):131-3, 138.

[3]. Hou RH, et al. Arousal and the pupil: why diazepam-induced sedation is not accompanied by miosis. Psychopharmacology (Berl). 2007 Nov;195(1):41-59.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA